title: Use of pentoxifylline in treatment of children with dengue hemorrhagic fever.
abstract: The current treatment for dengue hemorrhagic fever largely consists of supportive care. The drug pentoxifylline has been shown to blunt the proinflammatory actions of tumor necrosis factor-α, a key mediator of dengue hemorrhagic fever. We performed a pilot study evaluating pentoxifylline's effect on 55 children with dengue hemorrhagic fever. We believe our findings support the existing literature on its potential use in severe infection.
authors.affiliation: Department of Pediatrics, Universidad Surcolombiana, Neiva, Colombia.
authors.forename: Doris
authors.initials: D
authors.lastname: Salgado
authors.forename: Tatiana Esther
authors.initials: TE
authors.lastname: Zabaleta
authors.forename: Steven
authors.initials: S
authors.lastname: Hatch
authors.forename: Marta Rocio
authors.initials: MR
authors.lastname: Vega
authors.forename: Jairo
authors.initials: J
authors.lastname: Rodriguez
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D007223:Infant; D008297:Male; D010431:Pentoxifylline / Q000008:administration & dosage*; D011446:Prospective Studies; D019595:Severe Dengue / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D007155:Immunologic Factors; D014409:Tumor Necrosis Factor-alpha; D010431:Pentoxifylline